Publication date: Oct 01, 2025
Following the trends of the adult obesity epidemic, and worsened by school disruptions during the coronavirus disease 2019 pandemic, childhood obesity prevalence has reached unprecedented levels. The health implications for this generation are especially concerning, as childhood-onset obesity has more severe health consequences than weight gain that begins in adulthood, including increased risk of type 2 diabetes and diabetes-related complications. The complexity of obesity treatment has been challenging, including remarkable heterogeneity in obesity phenotypes and treatment responses among both adults and children. Many in the field have therefore highlighted a need for precision medicine approaches in obesity treatment across age-groups. This includes a need for precision risk stratification to better target treatment intensity, which will require a better understanding of the earliest stages of metabolic syndrome pathophysiology. The health, function, and distribution of adipose tissue have been established as important determinants of metabolic health in both childhood- and adult-onset obesity, making adipose tissue a promising target for understanding phenotypic heterogeneity in obesity. Here, we provide a brief overview of the current limited understanding of adipose tissue biology during childhood development and discuss opportunities for further research into adipose-centric precision medicine approaches in childhood-onset obesity and type 2 diabetes. Treatment options for childhood obesity are expanding, but precision medicine approaches, including strategies for precision risk assessment, are needed to appropriately target treatment intensity. Parameters of adipose tissue dysfunction are better predictors of metabolic syndrome than body size, and therefore adipose tissue represents a prime candidate for research approaches in understanding the pathophysiology of insulin resistance and in identifying biomarkers of future prognosis. Expanded developmental research on pediatric adipose tissue in both mice and humans is needed to understand the pathophysiology of childhood-onset obesity and to develop precision treatment approaches.

| Concepts | Keywords |
|---|---|
| Biomarkers | Adipose Tissue |
| Coronavirus | Child |
| Earliest | COVID-19 |
| Insulin | Diabetes Mellitus, Type 2 |
| Obesity | Humans |
| Pediatric Obesity | |
| Precision Medicine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Childhood Obesity |
| disease | MESH | obesity |
| disease | MESH | coronavirus disease 2019 |
| disease | MESH | weight gain |
| disease | MESH | type 2 diabetes |
| disease | MESH | diabetes-related complications |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | metabolic syndrome |
| disease | MESH | insulin resistance |
| pathway | KEGG | Insulin resistance |